This site is intended for healthcare professionals

Round Up Email July 2021

In this month's Round Up highlights include guidance regarding the use of antidrepressants in coronary heart disease; and the implications of a raised CK on statin treatment.

  • Question 1

    Multisystem inflammatory syndrome in children (MIS-C) – what is this condition? Is it similar to Kawasaki's disease? Is steroid treatment beneficial for children affected by MIS-C?: Multisystem inflammatory syndrome in children (MIS-C)

    1) Which statement regarding MIS-C is false?

  • Question 2

    Antibiotic treatment for acute diverticulitis – if a patient is managed in primary care and oral antibiotics are given then is cefalexin and metronidazole the first-choice antibiotic regime or is it co-amoxiclav alone?: Non surgical management (including suggested antibiotic regimes) of acute diverticulitis

    2) Which statement regarding antibiotic treatment in acute diverticulitis is false?

  • Question 3

    Raised CK on statin treatment: Myalgia and myositis associated with statin treatment

    3) Which statement regarding a raised CK on statin treatment is false?

  • Question 4

    Antidepressants if coronary heart disease – this subject is summarised on GPnotebook.: Depression and heart disease

    4) Which statement regarding antidepressant treatment in coronary heart disease is false?

  • Question 5

    Use of tamoxifen if no personal history of breast cancer – when is tamoxifen indicated in a woman with no personal history of breast cancer? For how long should the tamoxifen therapy be continued in this scenario?: Chemoprevention if no personal history of breast cancer

    5) Which statement regarding the use of tamoxifen if no personal history of breast cancer is false?

  • Question 6

    SGLT2 use versus use of sulphonylureas – a recent study has compared the all-cause mortality of these two diabetic therapies. The results of this study suggest that, compared with sulfonylureas, SGLT2 inhibitor use was associated with reduced risk of all-cause mortality among individuals using metformin for treatment of type 2 diabetes. But how did use of metformin affect the results of this study?: SGLT2 inhibitors in comparison to sulphonylureas (SUs) - comparison of all-cause mortality

    6) Which statement regarding comparing SGLT2 inhibitors and sulphonylureas is false?

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.